Pfizer Inc. (NYSE:PFE) Shares Bought by IFM Investors Pty Ltd

IFM Investors Pty Ltd raised its position in Pfizer Inc. (NYSE:PFEGet Rating) by 21.2% in the 1st quarter, according to its most recent filing with the SEC. The firm owned 878,033 shares of the biopharmaceutical company’s stock after acquiring an additional 153,642 shares during the period. Pfizer makes up 0.7% of IFM Investors Pty Ltd’s investment portfolio, making the stock its 23rd largest holding. IFM Investors Pty Ltd’s holdings in Pfizer were worth $45,456,000 at the end of the most recent quarter.

Several other hedge funds also recently made changes to their positions in PFE. NewEdge Wealth LLC raised its position in Pfizer by 64.7% during the fourth quarter. NewEdge Wealth LLC now owns 128,811 shares of the biopharmaceutical company’s stock worth $7,606,000 after acquiring an additional 50,611 shares during the last quarter. D.A. Davidson & CO. raised its position in Pfizer by 0.4% during the fourth quarter. D.A. Davidson & CO. now owns 675,671 shares of the biopharmaceutical company’s stock worth $39,877,000 after acquiring an additional 2,700 shares during the last quarter. Carmel Capital Partners LLC acquired a new position in Pfizer during the fourth quarter worth about $828,000. Harrison & Co Wealth Management LLC acquired a new position in Pfizer during the fourth quarter worth about $1,455,000. Finally, Peterson Financial Group Inc. acquired a new position in Pfizer during the fourth quarter worth about $5,883,000. Institutional investors and hedge funds own 66.50% of the company’s stock.

Pfizer Trading Up 0.2 %

Shares of PFE stock opened at $50.61 on Tuesday. The stock has a market cap of $283.97 billion, a price-to-earnings ratio of 9.90, a price-to-earnings-growth ratio of 0.62 and a beta of 0.67. The company has a quick ratio of 1.13, a current ratio of 1.39 and a debt-to-equity ratio of 0.43. Pfizer Inc. has a fifty-two week low of $40.94 and a fifty-two week high of $61.71. The firm’s 50 day moving average price is $51.42 and its two-hundred day moving average price is $51.19.

Pfizer (NYSE:PFEGet Rating) last posted its earnings results on Thursday, July 28th. The biopharmaceutical company reported $2.04 EPS for the quarter, topping analysts’ consensus estimates of $1.95 by $0.09. Pfizer had a net margin of 28.92% and a return on equity of 44.38%. The business had revenue of $27.74 billion for the quarter, compared to analysts’ expectations of $26.20 billion. During the same period in the previous year, the company posted $1.07 earnings per share. The business’s revenue for the quarter was up 46.8% compared to the same quarter last year. On average, analysts anticipate that Pfizer Inc. will post 6.53 EPS for the current year.

Pfizer Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Tuesday, September 6th. Stockholders of record on Wednesday, June 29th will be given a dividend of $0.40 per share. The ex-dividend date of this dividend is Thursday, July 28th. This represents a $1.60 dividend on an annualized basis and a dividend yield of 3.16%. Pfizer’s payout ratio is currently 31.31%.

Insider Transactions at Pfizer

In other news, SVP Jennifer B. Damico sold 4,218 shares of the business’s stock in a transaction on Tuesday, June 7th. The shares were sold at an average price of $53.96, for a total transaction of $227,603.28. Following the transaction, the senior vice president now directly owns 10,846 shares of the company’s stock, valued at $585,250.16. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. In related news, SVP Jennifer B. Damico sold 4,218 shares of the company’s stock in a transaction on Tuesday, June 7th. The shares were sold at an average price of $53.96, for a total value of $227,603.28. Following the sale, the senior vice president now directly owns 10,846 shares of the company’s stock, valued at $585,250.16. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, SVP Jennifer B. Damico sold 4,000 shares of the company’s stock in a transaction on Monday, May 16th. The shares were sold at an average price of $50.50, for a total transaction of $202,000.00. Following the completion of the sale, the senior vice president now directly owns 15,064 shares in the company, valued at $760,732. The disclosure for this sale can be found here. Over the last three months, insiders have sold 41,126 shares of company stock valued at $2,075,003. Corporate insiders own 0.05% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities analysts have issued reports on the stock. Citigroup lifted their target price on shares of Pfizer from $46.00 to $57.00 and gave the stock a “neutral” rating in a research report on Tuesday, April 5th. Berenberg Bank set a $50.00 price target on shares of Pfizer in a report on Friday, May 27th. StockNews.com upgraded shares of Pfizer from a “buy” rating to a “strong-buy” rating in a report on Tuesday, April 19th. JPMorgan Chase & Co. set a $57.00 price target on shares of Pfizer in a report on Tuesday, June 28th. Finally, The Goldman Sachs Group set a $50.00 price target on shares of Pfizer in a report on Friday. Nine analysts have rated the stock with a hold rating, ten have issued a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, Pfizer currently has a consensus rating of “Moderate Buy” and an average target price of $57.50.

Pfizer Company Profile

(Get Rating)

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands.

Featured Stories

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFEGet Rating).

Institutional Ownership by Quarter for Pfizer (NYSE:PFE)

Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.